Novartis Bets $12 Billion on RNA: Inside Its Bold Move to Dominate Rare Disease
This article is sponsored by Career Angel.ai! Novartis Bets $12 Billion on RNA: Inside Its Bold Move to Dominate Rare Disease The Headline Moment Swiss pharmaceutical giant Novartis (NYSE: NVS) has agreed to acquire Avidity Biosciences (NASDAQ: RNA) in a $12 billion all-cash deal, marking one of its largest U.S. biotech takeovers in years. The […]
Novartis Bets $12 Billion on RNA: Inside Its Bold Move to Dominate Rare Disease Read More »